Methodology article

BMC Bioinformatics

, 10:42

Selecting control genes for RT-QPCR using public microarray data

  • Vlad PopoviciAffiliated withBioinformatics Core Facility, Swiss Institute of Bioinformatics Email author 
  • , Darlene R GoldsteinAffiliated withBioinformatics Core Facility, Swiss Institute of BioinformaticsInstitut de mathématiques (IMA), Ecole Polytechnique Fédérale de Lausanne (EPFL)
  • , Janine AntonovAffiliated withDepartment of Clinical Research, University of Bern
  • , Rolf JaggiAffiliated withDepartment of Clinical Research, University of Bern
  • , Mauro DelorenziAffiliated withBioinformatics Core Facility, Swiss Institute of Bioinformatics
  • , Pratyaksha WirapatiAffiliated withBioinformatics Core Facility, Swiss Institute of Bioinformatics

10.1186/1471-2105-10-42

Abstract

Background

Gene expression analysis has emerged as a major biological research area, with real-time quantitative reverse transcription PCR (RT-QPCR) being one of the most accurate and widely used techniques for expression profiling of selected genes. In order to obtain results that are comparable across assays, a stable normalization strategy is required. In general, the normalization of PCR measurements between different samples uses one to several control genes (e.g. housekeeping genes), from which a baseline reference level is constructed. Thus, the choice of the control genes is of utmost importance, yet there is not a generally accepted standard technique for screening a large number of candidates and identifying the best ones.

Results

We propose a novel approach for scoring and ranking candidate genes for their suitability as control genes. Our approach relies on publicly available microarray data and allows the combination of multiple data sets originating from different platforms and/or representing different pathologies. The use of microarray data allows the screening of tens of thousands of genes, producing very comprehensive lists of candidates. We also provide two lists of candidate control genes: one which is breast cancer-specific and one with more general applicability. Two genes from the breast cancer list which had not been previously used as control genes are identified and validated by RT-QPCR. Open source R functions are available at http://​www.​isrec.​isb-sib.​ch/​~vpopovic/​research/​

Conclusion

We proposed a new method for identifying candidate control genes for RT-QPCR which was able to rank thousands of genes according to some predefined suitability criteria and we applied it to the case of breast cancer. We also empirically showed that translating the results from microarray to PCR platform was achievable.

Background

Real-time quantitative reverse transcription PCR (RT-QPCR) has become a method of choice for gene expression profiling in a large number of applications. However, obtaining reliable measurements still depends on the choice of control genes on which the baseline level is constructed. Selecting the control genes remains a critical point in the normalization process. Often, a short list of candidates is produced based on non-systematic and/or often poorly defined biological considerations.

In early studies, normalization was usually based on a single control gene. More recently, the trend is to use several control genes whose average expression level (on a log-scale) is used as baseline [1, 2]. Suitable control genes are selected from a short list of 10–15 genes by ranking them according to a criterion that essentially selects those genes having low variation across samples. We describe brie y a few such methods below.

[2] introduces a stability coefficient which is used along with the coefficient of variation for ranking the genes from a predefined list of candidates. Gene stability is defined in terms of average standard deviation of the log-ratios of pairs of candidate genes. Genes are ranked by iteratively removing those most unstable. This approach has the drawback that repeated comparison of pairs of genes is required, which is feasible only when the number of candidates is small. In addition, the method implicitly assumes that there are no co-regulated genes. A model-based approach proposed by [1] aims at estimating the overall variation as well as the between sample variation of each candidate gene. However, with this approach it is cumbersome to integrate different platforms. In an application to plant pathogen profiling, [3] investigates a list of 18 pre-selected candidate housekeeping genes, using the method proposed in [2] and RT-QPCR for measuring the gene expressions. [4] proposes a PCA-based statistical analysis to identify the most suitable control genes among 13 candidates which were selected such that they had independent functions in cellular maintenance.

[5] introduces a strategy which combines the coefficient of variation, maximum fold change and mean expression value in a ranking criterion that is applied to a large number of samples representing a wide variety of tissues. All these samples were hybridized on either Affymetrix HG-U133A or HG-U133 Plus 2.0 arrays and quantile-normalized together prior to ranking. Only probesets common to both arrays were used, with probesets targeting the same gene averaged into a single value.

There are some important differences between the methods described above and our approach (described below). Firstly, in contrast with all the studies based on PCR, we do not require a short list of candidate genes to be produced before assessing their suitability as control genes. Instead, we screen all the genes represented on the microarray chips, giving us the opportunity to assess genes that have not been reported previously. Moreover, we take a meta-analytical approach to the problem, first creating an independent ranking within each data set then aggregating these rankings into a single list. This approach has the advantage of being platform- and normalization-independent. In addition, the approach is not limited to using only genes common between different data sets. Also, by not using the coefficient of variation, we can treat uniformly both single and two-colors arrays. Thus, we are able to exploit data obtained from different platforms without requiring them to be normalized together. Furthermore, the meta-analytical approach allows us to integrate gene lists produced using our ranking system with other ranked gene lists from the literature and we do not require all data to be normalized together. Another key difference is that we introduce a new stability coefficient that combines the mean expression and the standard deviation in a ranking criterion that corresponds to our requirements for candidate control genes for RT-QPCR. In general, these requirements are:

  • low variability across different specimens (e.g., subtypes of tumors or normal tissues);

  • high and moderate level of expression, such that control genes with expression levels across a larger range may be selected;

  • consistency across experiments and platforms.

A key question is whether it is possible to select genes from microarray studies that perform as control genes on PCR platform, given that the two technologies are different. We hypothesize that translating the list of candidate genes from microarray to PCR platform is feasible and we provide empirical evidence in this sense.

Results

Data sets and pre-processing steps

We have collected ten publicly available data sets [615], listed in Table 1, from which we derived the quantities of interest: the mean and standard deviations of the log-intensities (on Affymetrix platforms) or of the log-ratios (on Agilent platforms).
Table 1

The ten public microarray data sets used (n = number of samples).

Data set ID and reference

n

Platform

BWH [6]

47

Affymetrix U133v2

EMC [7]

286

Affymetrix U133A

EXPO [8]

1375

Affymetrix U133Plus2

JRH2 [9]

61

Affymetrix U133A

MGH [10]

60

Agilent

NKI [11]

337

Agilent (custom)

STOCK [12]

159

Affymetrix U133A, B

TGIF1 [13]

49

Affymetrix U133A

UNC [14]

153

Agilent HuA1

UPP [15]

249

Affymetrix U133A, B

We note here that the original EXPO data set contains a number of different pathologies, but we restrict analysis here to eight different types of cancer (breast, colon, endometrium, kidney, lung, ovary, prostate and uterus) for which a sufficient number of samples existed. EXPO breast cancer samples (n = 328) were used to produce both the breast cancer and general cancer lists of candidate genes.

The Affymetrix data are available as MAS5.0 normalized values. The Agilent data contains log-ratios (base 10) and mean-centered log-intensities. The standard deviations of log-intensities (Affymetrix) and log-ratios (Agilent) were used as measures of variability. The means of log-intensities (both Affymetrix and Agilent) were used as measures of average expression level.

When multiple probesets of the same gene are present, only the most variable one is used. We consider all genes from each platform, the aggregation methods used being able to cope with 'missing' genes (those not represented on the array). Considering only those genes common to all platforms is an unnecessary limiting constraint, as increasing the number of data sets and the heterogeneity of the collection leads to a successively smaller intersection of genes.

Before any further usage of the data, we reduce the variability across platforms by scaling with a factor given by a first order LOESS fit of the data. The effect of this transformation can be seen in Figure 1, where the black line represents the fitted curve. This simple approach seems effective, except for genes with low expression. However, as we are interested in genes with higher mean expression, this deficiency is not problematic.
http://static-content.springer.com/image/art%3A10.1186%2F1471-2105-10-42/MediaObjects/12859_2008_Article_2772_Fig1_HTML.jpg
Figure 1

Example of variance stabilization by LOESS correction. LOESS correction applied to three data sets: BWH, NKI and EXPO-breast, respectively. The first row shows the original data with the fitted first order LOESS curve, while the second row shows the variance-stabilized data.

Ranking the genes

Let us consider that we have M microarray data sets, each containing expression values of a set of genes G k , k = 1,...,M, and let G = ∪ k G k = {1,...,N} be the set of all genes represented at least once in any of these data sets.

Gene scores

We aim to design a scoring function which ranks the genes such that higher scores correspond to genes that are more suitable to be used as control genes. As mentioned above, the score has to combine each gene's mean expression and standard deviation into a single value such that higher expression levels and lower variances (standard deviations) are favored. Moreover, the score must be independent of the technology used to measure expression levels and the method for normalization.

These requirements lead us to propose a new stability score for the gene expression levels. This score for gene i in data set k, denoted s ik , is defined as
http://static-content.springer.com/image/art%3A10.1186%2F1471-2105-10-42/MediaObjects/12859_2008_Article_2772_Equ1_HTML.gif
(1)
where http://static-content.springer.com/image/art%3A10.1186%2F1471-2105-10-42/MediaObjects/12859_2008_Article_2772_IEq1_HTML.gif and http://static-content.springer.com/image/art%3A10.1186%2F1471-2105-10-42/MediaObjects/12859_2008_Article_2772_IEq2_HTML.gif are the estimated mean log-intensity and the standard deviation of the gene i in data set k. The α coefficient allows the user to control the trade-off between the mean expression and the standard deviation in gene scoring. Results reported here were obtained with α = 0.25. The β k parameter allows one to define the level of mean expression below which the genes are not considered for ranking, i.e. the score for these genes is -∞. We have set β k to be the 25th percentile of the mean expression, for each data set k. Genes having a higher score are considered more suitable as control genes. As we see from Eq. 1, high variation in gene expression leads to a lower score when mean expression levels are equal. This is one reason we select the most highly variable probeset from the probesets representing the same gene, in order to encompass the worst-case scenario. Note also that there is no need to normalize the scores to make them comparable across data sets, because they are used solely for ranking the genes within the same data set. Finally, having computed the scores for all the genes within a data set, we order the genes from high to low values of the scores, with ties resolved by ordering by the mean expression (from high to low). From this perspective, the scores can be seen as defining classes of equivalence among genes: all the genes in the same class (having the same score) are equally useful as normalization genes. By using the second ordering criterion, we can select control genes with a desired expression level (examples of classes of equivalence are the equal score levels in Figure 2).
http://static-content.springer.com/image/art%3A10.1186%2F1471-2105-10-42/MediaObjects/12859_2008_Article_2772_Fig2_HTML.jpg
Figure 2

Scatter plots of standard deviation versus mean log-intensity for BWH, NKI and EXPO-breast data sets, respectively. The shading codes the gene stability scores, with darker colors indicating higher scores. These three data sets are from different microarray platforms. The light gray points indicate the discarded genes (those with mean expression level below the β value – see Eq. 1). The curves correspond to equal score levels and are one score unit apart.

Figure 2 displays the influence of the mean expression level and the standard deviation on the gene score. All genes located on the curves have the same score value (they belong to the same equivalence class). Two consecutive curves are separated by one score unit.

Using this stability score, we ranked the genes from each data set, obtaining the lists that will be later combined. An excerpt from the ten lists for the breast cancer data sets is shown in Table 2 (first ten columns).
Table 2

Top 20 control genes from the ten breast cancer data sets and top 20 genes from the aggregated list (Meta column)

BWH

EMC

JRH2

MGH

NKI

STOCK

TGIF1

UNC

UPP

EXPO-breast

Meta

RPL37A

PPIA

RPL41

ZNF557

UBC

RPS11

RPL41

RPS10

RPL9

CALM2

RPL37A

RPL41

CALM2

RPL39

CDR1

UBB

RPS24

RPL37A

RPS18

RPL37A

HNRPA1

RPL27A

RPS18

SRP14

RPL23A

PPP1R2

OAZ1

RPL9

EEF1A1

RPLP1

ACTG1

NACA

RPS18

RPL39

RPL37A

RPL37A

TCN2

DYNLL1

RPL37A

RPL30

RPS11

RPL27A

UBA52

RPL30

RPL23A

RPS18

EEF1A1

SSBP1

RAPSN

RPL41

RPL39

RPS23

CFL1

LAPTM4A

RPL41

RPL9

RPL30

RPS23

RPL27A

PCBP1

RPL27A

PPIA

RPL37A

RPS11

RPL27A

CALM2

RPLP1

RPL27A

RPS27

RPS3

KCNH3

RPL39

ACTG1

RPL11

RPS13

RPL30

RPL27

RPS27

RPS11

CALM2

BRCC3

RPL3

RPLP1

CFL1

RPS15

RPL27

RPL9

K-ALPHA-1

RPL27A

RPL39

RPS18

PTMA

RPL8

UBB

RPS23

RPL14

RPL41

RPL31

RPS11

RPL30

RPS15

ACTG1

ABCF2

MYL6

RPS15A

RPL10

NACA

RPS18

RPL37

RPL39

RPS29

RPS24

RPL10

PCDH18

RPL14

CALM2

CALM2

RPL36AL

RPS15

RPS11

RPS13

ACTG1

RPL32

RPS24

LAX1

RPL7A

NACA

RPS11

UBA52

RPL6

RPS29

NACA

CALM2

RPS15A

RPS15A

TPMT

FAU

RPL30

HNRPA1

NEDD8

RPLP1

RPS24

RPL23A

RPS13

RPLP1

RPL32

GALE

ARF1

CFL1

RPL6

PCBP1

RPL32

RPS13

RPS24

HNRPA1

RPL9

RPL27A

MTCH1

CCT3

RPS13

RPL23A

NDUFB2

RPL31

RPS21

HNRPA1

RPS24

UBB

UBB

ATP5G2

PSAP

RPS3A

K-ALPHA-1

HNRPM

RPL39

UBB

RPL9

RPL31

K-ALPHA-1

RPS29

SF3B2

CD81

RPL37

RPS18

HNRPC

UBB

RPS27A

RPLP1

RPL34

RPS13

RPL30

SND1

SQSTM1

RPS18

EEF1G

NDUFB8

RPS24

RPS15

RPL32

RPS15A

RPL27

PPIA

RPL5

K-ALPHA-1

RPL27

TUBA6

ATP5J2

RPS27

RPL32

LAPTM4A

RPS21

FAU

CFL1

SKAP2

CALR

RPL24

RPS3A

TARDBP

DDX5

RPL24

RPS15A

Combining results from different data sets

Once genes are ranked according to their scores in each data set (lower ranks correspond to higher scores), the natural next step is to combine these rankings into a global ranked list. We combine the ranks of the genes rather than their scores to avoid normalizing the scores across different data sets, thereby achieving platform-independence. To this end we use the rank product score [16], which is a fast and efficient method for combining ranked lists. It computes, for each gene iG, a new score
http://static-content.springer.com/image/art%3A10.1186%2F1471-2105-10-42/MediaObjects/12859_2008_Article_2772_Equ2_HTML.gif
(2)

where rank k (i) is the rank of s ik , the score for gene i in data set k (topmost gene has the rank 1), and n i is the number of data sets in which the gene i appears. The final list is obtained by sorting the genes in increasing order of R i . The top 20 genes from the aggregated breast cancer list are given in the 'Meta' (last) column of Table 2.

Validation of the aggregated lists

There is no absolute criterion by which one can judge the quality of the resulting lists. Rather, the aggregated list could be used to select from the top genes (100, for example) those genes that also satisfy further conditions of the specific application.

We can, however, have a subjective impression of the validity of the aggregated list by visualizing the resulting top genes in data sets not used for producing the list. We obtained a list of the top 100 genes by applying the method described above on eight of the ten data sets, leaving NKI and UPP aside as validation sets. The top 100 genes in both validation sets (different microarray platforms) are plotted in Figure 3. As a comparison, we also include the five control genes used in [17] (represented as triangles in the figure). It is seen that the genes are generally concentrated in the lower right part of the plot, corresponding to high mean expression levels and low variance. There is a notable difference between the quality of the results (given by the concentration of the control genes in the lower right corner) on the two platforms, due to the fact that most of the data sets used for gene selection are from Affymetrix platforms. While the top 100 lists contain genes with high stability scores on the Affymetrix platforms (the UPP data set), on the custom Agilent platform (NKI) there are a number of genes that are missed. Nevertheless, those selected still function well as control genes.
http://static-content.springer.com/image/art%3A10.1186%2F1471-2105-10-42/MediaObjects/12859_2008_Article_2772_Fig3_HTML.jpg
Figure 3

Scatter plots of standard deviation versus mean log-intensity for two validation data sets (from left to right: NKI and UPP). The top 100 breast cancer control genes resulting from aggregating eight data sets are plotted as circles. Triangles correspond to the five control genes used in [17] (NKI does not contain the ACTB gene).

Control genes lists

We have analyzed ten different data sets which have samples hybridized on different versions of Agilent and Affymetrix platforms. Using our proposed method, we compiled two different lists of candidate control genes: one specific to breast cancer [see Additional file 1] and one resulting from the analysis of eight different types of cancer, thus applicable to cancers in general [see Additional file 2]. From the breast cancer list we selected two new control genes which were validated in an RT-QPCR assay that also included five previously used control genes (ACTB, TFRC, GUSB, RPLP0 and GAPDH – see [17]) and breast cancer-related genes (e.g. ESR1, ERBB2, AURKA, etc.). The RT-QPCR results confirm the findings from the microarray analysis and show that more stably expressed control genes can be selected by applying the criteria mentioned above. Also, they provide empirical evidence supporting the working hypothesis that PCR control genes can be selected from microarray data.

The list of the top 50 control genes obtained from the ten breast cancer data sets is given in Table 3. More comprehensive lists, including one containing the top 2000 candidate breast cancer genes and a similar list compiled from eight different types of cancer, are available [see Additional file 1 and Additional file 2]. In the case of breast cancer control genes, it is interesting to note that some of the "classical" genes (e.g. ACTB, GAPDH, TFRC) are not among the top 50.
Table 3

Top 50 control genes as resulting from aggregating the ten breast cancer data sets. Two genes – RPS11 and UBB – were selected as control genes and validated by RT-PCR

Rank

Gene symbol

Gene ID

Description

1

RPL37A

6168

ribosomal protein L37a

2

RPL27A

6157

ribosomal protein L27a

3

RPS18

6222

ribosomal protein S18

4

RPL30

6156

ribosomal protein L30

5

RPL41

6171

ribosomal protein L41

6

CALM2

805

calmodulin 2 (phosphorylase kinase, delta)

7

RPL27

6155

ribosomal protein L27

8

K-ALPHA-1

10376

alpha tubulin

9

RPS11

6205

ribosomal protein S11

10

RPL39

6170

ribosomal protein L39

11

RPS13

6207

ribosomal protein S13

12

NACA

4666

nascent-polypeptide-associated complex alpha polypeptide

12

RPL23A

6147

ribosomal protein L23a

14

RPS24

6229

ribosomal protein S24

15

HNRPA1

3178

heterogeneous nuclear ribonucleoprotein A1

16

RPL9

6133

ribosomal protein L9

17

RPLP1

6176

ribosomal protein, large, P1

18

RPL32

6161

ribosomal protein L32

19

LAPTM4A

9741

lysosomal-associated protein transmembrane 4 alpha

20

RPS15A

6210

ribosomal protein S15a

21

DYNLL1

8655

dynein, light chain, LC8-type 1

22

ACTG1

71

actin, gamma 1

23

TUBA6

84790

tubulin, alpha 6

24

SRP14

6727

signal recognition particle 14kDa (homologous Alu RNA binding protein)

25

MYL6

4637

myosin, light chain 6, alkali, smooth muscle and non-muscle

26

RPL24

6152

ribosomal protein L24

27

FAU

2197

Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) ubiquitously expressed (fox derived); ribosomal protein S30

28

RPL31

6160

ribosomal protein L31

29

RPS15

6209

ribosomal protein S15

30

MTCH1

23787

mitochondrial carrier homolog 1 (C. elegans)

31

UBB

7314

ubiquitin B

32

RPL37

6167

ribosomal protein L37

33

HMGN2

3151

high-mobility group nucleosomal binding domain 2

34

RPS27

6232

ribosomal protein S27 (metallopanstimulin 1)

35

GDF8

2660

growth differentiation factor 8

36

RPL38

6169

ribosomal protein L38

37

RPS29

6235

ribosomal protein S29

38

SULT1C2

27233

sulfotransferase family, cytosolic, 1C, member 2

39

RPL6

6128

ribosomal protein L6

40

UBC

7316

ubiquitin C

41

UBA52

7311

ubiquitin A-52 residue ribosomal protein fusion product 1

42

MRFAP1

93621

Mof4 family associated protein 1

43

HNRPK

3190

heterogeneous nuclear ribonucleoprotein K

44

PARK7

11315

Parkinson disease (autosomal recessive, early onset) 7

45

PSMC1

5700

proteasome (prosome, macropain) 26S subunit, ATPase, 1

46

LOC158572

158572

hypothetical protein LOC158572

47

RPS8

6202

ribosomal protein S8

48

ATP5A1

498

ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, cardiac muscle

49

EIF4H

7458

eukaryotic translation initiation factor 4H

50

CD63

967

CD63 molecule

Evaluation of control genes by RT-QPCR

Motivated by the consistency of the selection process for suitable control genes among different microarray platforms, we performed a small scale RT-QPCR experiment to test the performance of two new control genes along with a number of more commonly used control genes. In this experiment, RNA was isolated from 25 cryo-preserved breast cancer samples and the expression of 47 genes was measured by RT-QPCR [18]. Test genes were selected according to their relatedness to proliferation or estrogen receptor functions. Some of the test genes had been previously identified and used for characterizing primary breast cancers [17]. Two genes, RPS11 and UBB, ranked 9 and 31 in Table 3 respectively, were compared to five additional control genes and to a number of test genes previously measured by [17]. Mean raw expression values of all candidate control and test genes were plotted against standard deviations of each gene (Figure 4). The raw Ct (cycle threshold) value is the number of PCR cycles required for the fluorescence signal to cross the background threshold, so that low Ct values correspond to high expression levels. RPS11 and UBB are clearly among the most stably expressed genes, as their standard deviations are both quite low. Other genes frequently used as control genes are also shown. For comparison, mean expression and standard deviation of several test genes are also indicated. The expression of most test genes is much more variable than UBB and RPS11.
http://static-content.springer.com/image/art%3A10.1186%2F1471-2105-10-42/MediaObjects/12859_2008_Article_2772_Fig4_HTML.jpg
Figure 4

RT-QPCR experiment. Standard deviation as a function of the mean expression level (expressed as raw Ct values) of 47 genes in a RT-QPCR experiment. Higher expression levels correspond to smaller raw Ct values. Control genes are represented by triangles, test genes by circles. The new control genes RPS11 and UBB are in the lower left corner.

The two new control genes, together with RPLP0, offer the best trade-off between mean expression level and variability, while others like ACTB or TFRC are less stably expressed and therefore seem less suitable for use as normalization genes.

Discussion

We propose a new approach which leverages publicly available microarray data to produce lists of candidate control genes for RT-QPCR. Our method is independent of the microarray platform or normalization methodology, and is able to cope with gene lists that overlap only partially. After screening thousands of genes (generally more than 10,000 genes in each data set), we have produced two separate lists of candidate genes: one specific to breast cancer and one generally applicable to different types of cancer. We do not consider these lists as generally applicable, as the data used do not allow such generalization. Different pathologies may have a different impact on the control genes and some of the control genes we selected may become ineffective in the case of a disease which affects their particular functions. On the other hand, more diverse data should be used if the goal is finding global control genes. The list of the top 50 breast cancer control genes (Table 3) is dominated by ribosomal proteins. This finding is consistent with the fact that ribosomes are a major component of basic physiologic processes in all the cells and not a primary target of changing conditions. Other genes present among the first 50 genes code for protein turnover (ubiquitin), tubulin-related proteins or actins, structures which are required in all living cells.

Our results are supported by recent findings of de Jonge et al. [5], who used a different ranking method. In addition, the lists of control gene candidates for breast cancer and for diverse types of cancer are similar [see Additional file 1 and Additional file 2], as a large number of the top ranked genes belong to the same functional category (ribosomal genes, protein turnover).

Another important finding is that some of the commonly used control genes in breast cancer (ACTB and TFRC) appear to be less stable than previously assumed. This has an impact on the normalization strategy of the QPCR measurements: indeed, in our more recent experiments we have chosen to use the mean of RPLP0, RPS11 and UBB (on the log2 scale) for normalizing the expression of test genes.

Finally, we would like to emphasize that these two lists should not be taken in an absolute sense: a gene in top 10 is not necessarily a better choice than a gene in the top 20 to 30. But we do consider it to be definitely a better candidate than a gene not in top 100. Nor do we consider the resulting ranking as providing a solution to the problem of finding normalization genes in all contexts. Rather, the lists produced through this process are meant to guide the choice of control genes while also taking into consideration the specific requirements of any individual analysis. Depending on the planned application, other parameters must be considered. For example, short amplicons or intron-spanning primers must be used when the starting RNA is considerably degraded or when residual DNA contaminations might affect QPCR. The final choice of control genes should be made not by blind adherence to the ranked list, but be imposed by the intended application.

Conclusion

Starting from clearly defined criteria, we have designed a novel method for ranking the candidate genes for their suitability as control genes in RT-QPCR experiments. The genes from a data set were ranked according to their stability score, which represented a trade-off between gene's average expression level and its variance. Finally, the rankings from several data sets were combined into a list of candidate genes, with higher ranked genes being considered to be more suitable as control genes. The proposed approach had the advantage of being platform- and normalization- independent and of not being restricted to only the list of common genes across all data sets.

By applying the proposed method to two particular collections of data sets we were able to produce two lists of candidate genes from which control genes for either breast cancer or more diverse cancer could be easily selected. Two new control genes for breast cancer – UBB and RPS11 – have been identified and validated by RT-QPCR.

Our results support the hypothesis that selecting control genes for QPCR from microarray data is feasible.

Acknowledgements

This work has been funded by the Swiss National Science Foundation through the National Centre for Competence in Research (Molecular Oncology (MD, VP and PW)) and the National Centre for Competence in Research (Plant Survival (DRG)), and by the Swiss Cancer League (Project OCS 01704-04-2005 (RJ and MD)).

Copyright information

© Popovici et al. 2009

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.